(Q38246996)

1 September 2017

1 reference

title

Post-translational structural modifications of immunoglobulin G and their effect on biological activity (English)

1 reference

1 September 2017

Laura K Hmiel

1

1 reference

1 September 2017

Kurt A Brorson

series ordinal

2

1 reference

1 September 2017

Michael T Boyne

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

10 September 2014

1 reference

Analytical and Bioanalytical Chemistry

1 September 2017

published in

1 reference

1 September 2017

volume

407

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

79-94

1 reference

https://scigraph.springernature.com/pub.10.1007/s00216-014-8108-x

1 September 2017

exact match

0 references

cites work

Monoclonal antibodies as innovative therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Stability of IgG isotypes in serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Fcgamma receptors as regulators of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Overview of monoclonal antibodies in cancer therapy: present and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Current methods for the generation of human antibodies for the treatment of autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Optimal and consistent protein glycosylation in mammalian cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Industry and regulatory experience of the glycosylation of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Posttranslational modification of therapeutic proteins in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Attachment of carbohydrate to the variable region of myeloma immunoglobulin light chains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Glycosylation of a VH residue of a monoclonal antibody against alpha (1----6) dextran increases its affinity for antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The covalent structure of an entire gammaG immunoglobulin molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Glycosylation profiles of therapeutic antibody pharmaceuticals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Anti-inflammatory actions of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The antiinflammatory activity of IgG: the intravenous IgG paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Identification of a receptor required for the anti-inflammatory activity of IVIG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Antigen of “serum sickness” type of heterophile antibodies in human sera: Identification as gangliosides with N-glycolylneuraminic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

In vivo trafficking and catabolism of IgG1 antibodies with Fc associated carbohydrates of differing structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Fermentanomics informed amino acid supplementation of an antibody producing mammalian cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Defining process design space for monoclonal antibody cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Glycoprotein analysis using mass spectrometry: unraveling the layers of complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

A multi-method approach toward de novo glycan characterization: a Man-5 case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Quantitative glycomics strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Post-translational modifications differentially affect IgG1 conformation and receptor binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Agalactosyl glycoforms of IgG autoantibodies are pathogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

A unique natural human IgG antibody with anti-alpha-galactosyl specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Impaired allergy diagnostics among parasite-infected patients caused by IgE antibodies to the carbohydrate epitope galactose-α 1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Galactose-α-1,3-galactose-specific IgE is associated with anaphylaxis but not asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Naturally occurring glycan forms of human immunoglobulins G1 and G2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The effect of Fc glycan forms on human IgG2 antibody clearance in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Effects of cell culture conditions on antibody N-linked glycosylation--what affects high mannose 5 glycoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structure-immunogenicity relationships of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Robustness of iCIEF methodology for the analysis of monoclonal antibodies: an interlaboratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Top-down MS for rapid methionine oxidation site assignment in filgrastim

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Mass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Changes in avidity and specificity of IgG during electro-oxidation. Relevance of binding of antibodies to beta2-GPI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Protein aggregation and bioprocessing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Accurate identification of deamidated peptides in global proteomics using a quadrupole orbitrap mass spectrometer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Post-translational modifications of recombinant proteins: significance for biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Human antibody Fc deamidation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Assessing monoclonal antibody product quality attribute criticality through clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Antibody structure, instability, and formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Complete disulfide bond assignment of a recombinant immunoglobulin G4 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Human IgG2 antibody disulfide rearrangement in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Human IgG2 antibodies display disulfide-mediated structural isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Human IgG2 can form covalent dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Mechanism of immunoglobulin G4 Fab-arm exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Intrachain disulfide bond in the core hinge region of human IgG4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Folding and oxidation of the antibody domain C(H)3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Free sulfhydryl measurement as an indicator of antibody stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Role of oxidative stress in development of complications in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

The pathobiology of diabetic complications: a unifying mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

In vitro glycation of human immunoglobulin G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Preferential recognition of epitopes on AGE-IgG by the autoantibodies in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Glycation during storage and administration of monoclonal antibody formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Non-enzymatic glycation of IgG: an in vivo study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Multispecificity of immunoglobulin M antibodies raised against advanced glycation end products: involvement of electronegative potential of antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Characterization of therapeutic antibodies and related products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Structural comparison of two anti-CD20 monoclonal antibody drug products using middle-down mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Comparability assessments of process and product changes made during development of two different monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Quality assurance of monoclonal antibody pharmaceuticals based on their charge variants using microchip isoelectric focusing method

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Reversed-phase liquid chromatography/mass spectrometry analysis of reduced monoclonal antibodies in pharmaceutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Vascular leak syndrome: a side effect of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

A Role for Protein Misfolding in Immunogenicity of Biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00216-014-8108-X

10.1007/S00216-014-8108-X

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference